3% (39-47 mmol/mol) within 6 months before and 7 days after cohort entry (only available for 9419 low-dose quetiapine users [16%] and 38 340 SSRI users [5%] in the full cohort and for 8648 low-dose quetiapine users [16%] and 10 656 SSRI users [20%] in the hdPS
Jan 20, 2017 · 1.
May 3, 2021 · Importance: Quetiapine has been associated with increased risk of type 2 diabetes when used in medium or high doses for the treatment of severe mental disorders
puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
Use of low-dose quetiapine was
Conclusions: Atypical antipsychotic-induced diabetes does not always take a "type 2" presentation in which weight gain and insulin resistance are implicated
ABSTRACT: Several metabolic consequences of antipsychotic use have been described within the literature, including